Skip to main content
letter
. 2016 Sep;8(9):E1096–E1099. doi: 10.21037/jtd.2016.08.20

Table 1. Currently available scoring systems for CTO PCI.

Score variables J-CTO score (3) CL score (4) PROGRESS-CTO score (5) ORA score (6) Chai et al. (7) Wilson et al. (8) Liu et al. (9) CT-RECTOR score* (10) Ito et al.* (11)
Number of cases (n) 494 1,657 781 1,073 228 1,156 728 240 263
Endpoint GW crossing <30 min Technical success Technical success Technical success Technical success-retrograde Technical success CIN GW crossing ≤30 min MACE during follow-up‡
Age (years) + (≥75) + (>65) + (≥75)
Prior CABG + +
Prior failure + +
Proximal cap + (blunt) + (blunt) + (ambiguous) + (ostial) + + (blunt)
Tortuosity + (>45º in lesion) + (moderate†, proximal) + +
Calcification + + (severe) + + (severe) + (severe)
Lesion length + (≥20 mm) + (≥20 mm) + + (>25.4 mm)
Target vessel + (non-LAD) + (LCX)
Collateral quality + (lack of interventional) + (Rentrop <2) + (Werner, tortuous)
Other Prior myocardial infarction Distal segment diameter BMI >30; non-proximal location LVEF <40%; SCr >1.5 mg/dL Multiple occlusions; duration ≥12 months Minimal vessel area <11.9 mm2

*, computed tomography angiography based; , moderate tortuosity defined as 2 bends >70° or 1 bend >90° proximal to the lesion; , defined as cardiac death, myocardial infarction, stent thrombosis or target lesion revascularization at median 4.0 years follow-up; +, variable included in score. CTO, chronic total occlusion; PCI, percutaneous coronary intervention; J-CTO, multicenter CTO registry in Japan; CL, clinical and lesion-related; PROGRESS CTO, Prospective Global Registry For The Study of Chronic Total Occlusion Intervention; CT-RECTOR, Computed Tomography Registry of Chronic Total Occlusion Revascularization; ORA, ostial location, Rentrop grade <2, age ≥75 years; BMI, body mass index; CABG, coronary artery bypass grafting; CIN, contrast induced nephropathy; GW, guidewire; LAD, left anterior descending artery; LCX, circumflex artery; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; SCr, serum creatinine.